To bind or not to bind: Cistromic reprogramming in prostate cancer

Area of Science:

• * Molecular biology
• * Cancer research
• * Epigenetics

Background:

• * The cistrome, representing genome-wide transcription factor binding sites, is crucial for gene regulation.
• * In prostate cancer, the cistrome of key regulatory factors, including the androgen receptor (AR), is significantly altered during disease progression.
• * Aberrant expression or mutation of transcription factors like FOXA1, HOXB13, GATA2, ERG, and MYC contribute to AR cistrome reprogramming.

Purpose of the Study:

• * To review the role of cistromic reprogramming in prostate cancer initiation and progression.
• * To discuss the impact of key prostate cancer regulators on the AR cistrome.
• * To highlight the involvement of epigenetic and chromatin regulators in altering the AR cistrome.

Main Methods:

• * Review of existing literature on transcription factor binding, cistromic alterations, and epigenetic modifications in prostate cancer.
• * Analysis of the reprogramming of the androgen receptor (AR) cistrome by various transcription factors and chromatin remodelers.
• * Examination of the role of SWI/SNF complex and CHD1 in epigenome remodeling and AR cistrome alteration.

Main Results:

• * Cistromes of key regulatory factors are substantially reprogrammed during prostate cancer development and progression.
• * The androgen receptor (AR) cistrome is directly impacted and reprogrammed during malignant transformation.
• * Pioneer transcription factors (FOXA1, HOXB13, GATA2), ERG, MYC, and chromatin remodelers (SWI/SNF, CHD1) play critical roles in AR cistrome alterations.

Conclusions:

• * Cistromic reprogramming is a central mechanism in prostate cancer initiation and progression.
• * Understanding the dynamics of transcription factor-chromatin interactions provides insights into therapeutic strategies for prostate cancer.
• * Targeting altered cistromes and epigenetic regulators may offer novel treatment avenues.